ALK-Abelló A/S (ALK-B.CO)

DKK 146.4

(1.04%)

Operating Expenses Summary of ALK-Abelló A/S

  • ALK-Abelló A/S's latest annual operating expenses in 2023 was 2.36 Billion DKK , up 2.07% from previous year.
  • ALK-Abelló A/S's latest quarterly operating expenses in 2024 Q2 was 605 Million DKK , up 5.24% from previous quarter.
  • ALK-Abelló A/S reported a annual operating expenses of 2.32 Billion DKK in annual operating expenses 2022, up 10.31% from previous year.
  • ALK-Abelló A/S reported a annual operating expenses of 2.1 Billion DKK in annual operating expenses 2021, up 12.09% from previous year.
  • ALK-Abelló A/S reported a quarterly operating expenses of 605 Million DKK for 2024 Q2, up 5.24% from previous quarter.
  • ALK-Abelló A/S reported a quarterly operating expenses of 610 Million DKK for 2023 Q2, up 6.83% from previous quarter.

Annual Operating Expenses Chart of ALK-Abelló A/S (2023 - 2002)

Historical Annual Operating Expenses of ALK-Abelló A/S (2023 - 2002)

Year Operating Expenses Operating Expenses Growth
2023 2.36 Billion DKK 2.07%
2022 2.32 Billion DKK 10.31%
2021 2.1 Billion DKK 12.09%
2020 1.87 Billion DKK -2.34%
2019 1.92 Billion DKK 11.16%
2018 1.72 Billion DKK 0.41%
2017 1.72 Billion DKK 17.22%
2016 1.46 Billion DKK 2.01%
2015 1.44 Billion DKK 4.05%
2014 1.38 Billion DKK -2.26%
2013 1.41 Billion DKK -6.53%
2012 1.51 Billion DKK 5.35%
2011 1.43 Billion DKK 11.04%
2010 1.29 Billion DKK 10.49%
2009 1.17 Billion DKK 2.99%
2008 1.13 Billion DKK 21.71%
2007 935 Million DKK -0.43%
2006 939 Million DKK 17.08%
2005 802 Million DKK 0.0%
2004 - DKK 0.0%
2003 - DKK 0.0%
2002 - DKK 0.0%

Peer Operating Expenses Comparison of ALK-Abelló A/S

Name Operating Expenses Operating Expenses Difference
Bavarian Nordic A/S 3.02 Billion DKK 21.666%
Genmab A/S 10.92 Billion DKK 78.32%
Gubra A/S 164.35 Million DKK -1341.41%
Novo Nordisk A/S 93.92 Billion DKK 97.478%
Orphazyme A/S 27.04 Thousand DKK -8760670.682%
Pharma Equity Group A/S 24.81 Million DKK -9447.415%
Zealand Pharma A/S 226.92 Million DKK -943.939%